New Two-Drug attack tested against tough lung cancer
NCT ID NCT06512051
Summary
This study is testing the safety and effectiveness of a new drug called SHR-A2102 when given with an existing immunotherapy drug (adebrelimab), with or without other cancer therapies. It aims to find the best dose and see if this combination can help control advanced or spreading non-small cell lung cancer. The study will enroll about 248 adults whose cancer cannot be treated with surgery or cured with standard therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese People's Liberation Army General Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.